View Item 

Show simple item record

Comments on cochrane review on direct‐acting antivirals for hepatitis C
dc.contributor.authorLok, Anna S.
dc.contributor.authorChung, Raymond T.
dc.contributor.authorVargas, Hugo E.
dc.contributor.authorKim, Arthur Y.
dc.contributor.authorNaggie, Susanna
dc.contributor.authorPowderly, William G.
dc.date.accessioned2017-10-05T18:20:08Z
dc.date.available2019-01-07T18:34:38Zen
dc.date.issued2017-10
dc.identifier.citationLok, Anna S.; Chung, Raymond T.; Vargas, Hugo E.; Kim, Arthur Y.; Naggie, Susanna; Powderly, William G. (2017). "Comments on cochrane review on direct‐acting antivirals for hepatitis C." Hepatology 66(4): 1016-1019.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/138405
dc.publisherWiley Periodicals, Inc.
dc.publisherNational Academies Press
dc.titleComments on cochrane review on direct‐acting antivirals for hepatitis C
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138405/1/hep29366_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138405/2/hep29366.pdf
dc.identifier.doi10.1002/hep.29366
dc.identifier.sourceHepatology
dc.identifier.citedreferenceCurry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open‐label study. Gastroenterology 2015; 148: 100 ‐ 107.
dc.identifier.citedreferenceSaadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV‐associated cryoglobulinemia vasculitis. Gastroenterology 2017; 153: 49 ‐ 52.
dc.identifier.citedreferenceSise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, et al. Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents. Hepatology 2016; 63: 408 ‐ 417.
dc.identifier.citedreferenceGisbert JP, Pajares JM. Systematic review and meta‐analysis: is 1‐week proton pump inhibitor‐based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005; 21: 795 ‐ 804.
dc.identifier.citedreferenceHermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache‐Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89 ‐ 94.
dc.identifier.citedreferenceMazzaro C, Little D, Pozzato G. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 2168 ‐ 2170.
dc.identifier.citedreferenceTakahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012; 51: 2745 ‐ 2747.
dc.identifier.citedreferenceArcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, et al. Interferon‐free antiviral treatment in B‐cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 2016; 128: 2527 ‐ 2532.
dc.identifier.citedreferenceCharlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649 ‐ 659.
dc.identifier.citedreferenceCurry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618 ‐ 2628.
dc.identifier.citedreferenceBelli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016; 65: 524 ‐ 531.
dc.identifier.citedreferenceYoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck‐Radosavljevic M, et al. Persistence of virologic response after liver transplant in hepatitis C patients treated with ledipasvir/sofosbuvir plus ribavirin pretransplant. Ann Hepatol 2017; 16: 375 ‐ 381.
dc.identifier.citedreferenceManns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open‐label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16: 685 ‐ 697.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir and velpatasvir combination improves patient‐reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol 2017; 15: 421 ‐ 430.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Charlton M, Curry MP, O’Leary JG, Brown RS, et al. Patient‐reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus–related decompensated cirrhosis: an exploratory analysis from the randomised, open‐label ASTRAL‐4 phase 3 trial. Lancet Gastroenterol Hepatol 2016; 1: 122 ‐ 132.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, et al. Sofosbuvir/velpatasvir improves patient‐reported outcomes in HCV patients: results from ASTRAL‐1 placebo‐controlled trial. J Hepatol 2016; 65: 33 ‐ 39.
dc.identifier.citedreferenceNational Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Washington, DC: National Academies Press; 2016.
dc.identifier.citedreferenceNational Academies of Sciences, Engineering, and Medicine. A national strategy for the elimination of hepatitis B and C: phase two report. Washington, DC: National Academies Press; 2017.
dc.identifier.citedreferenceAmerican Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org. Accessed July 2, 2017.
dc.identifier.citedreferenceJakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct‐acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017; 6: CD012143.
dc.identifier.citedreferenceSimmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta‐analysis. Clin Infect Dis 2016; 62: 683 ‐ 694.
dc.identifier.citedreferenceSwain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa‐2a and ribavirin. Gastroenterology 2010; 139: 1593 ‐ 1601.
dc.identifier.citedreferencePoynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa‐2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303 ‐ 1313.
dc.identifier.citedreferenceMorgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck‐Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta‐analysis of observational studies. Ann Intern Med 2013; 158: 329 ‐ 337.
dc.identifier.citedreferencevan der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all‐cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584 ‐ 2593.
dc.identifier.citedreferenceVeldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677 ‐ 684.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep29366_am.pdf
Size:
139.1KB
Format:
PDF
View/Open
Name:
hep29366.pdf
Size:
126.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.